(Q36455993)

14 August 2017

title

Immune response modifiers--mode of action (English)

1 reference

14 August 2017

Meinhard Schiller

1

1 reference

14 August 2017

Dieter Metze

2

1 reference

14 August 2017

Thomas A Luger

3

1 reference

14 August 2017

Stephan Grabbe

4

1 reference

14 August 2017

Matthias Gunzer

5

1 reference

14 August 2017

publication date

1 May 2006

1 reference

14 August 2017

published in

Experimental Dermatology

1 reference

14 August 2017

volume

15

1 reference

14 August 2017

issue

5

1 reference

14 August 2017

page(s)

331-341

1 reference

How T cells 'see' antigen

14 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.0906-6705.2006.00414.X

Alpha-MSH reduces the internalization of Staphylococcus aureus and down-regulates HSP 70, integrins and cytokine expression in human keratinocyte cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0906-6705.2006.00414.X

The status quo and quo vadis of mast cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0906-6705.2006.00414.X

Interactions among stratum corneum defensive functions

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0906-6705.2006.00414.X

Innate immune recognition

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0906-6705.2006.00414.X

Self-administered topical 5% imiquimod cream for external anogenital warts. HPV Study Group. Human PapillomaVirus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0906-6705.2006.00414.X

Therapeutic response of basal cell carcinoma to the immune response modifier imiquimod 5% cream

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0906-6705.2006.00414.X

The Toll gene of Drosophila, required for dorsal-ventral embryonic polarity, appears to encode a transmembrane protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0906-6705.2006.00414.X

The dorsoventral regulatory gene cassette spätzle/Toll/cactus controls the potent antifungal response in Drosophila adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0906-6705.2006.00414.X

MyD88 is an adaptor protein in the hToll/IL-1 receptor family signaling pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0906-6705.2006.00414.X

The Toll‐like receptor 7 (TLR7)‐specific stimulus loxoribine uncovers a strong relationship within the TLR7, 8 and 9 subfamily

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0906-6705.2006.00414.X

TLR9 signals after translocating from the ER to CpG DNA in the lysosome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0906-6705.2006.00414.X

TRAF6 is a signal transducer for interleukin-1

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0906-6705.2006.00414.X

T-cell-receptor- and B-cell-receptor-mediated activation of NF-kappaB in lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0906-6705.2006.00414.X

IRAK-M is a negative regulator of Toll-like receptor signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0906-6705.2006.00414.X

Regulation of the immune system by SOCS family adaptor proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0906-6705.2006.00414.X

Regulation of TLR signaling and inflammation by SOCS family proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0906-6705.2006.00414.X

Modification of immunological responses and clinical disease during topical R-837 treatment of genital HSV-2 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0906-6705.2006.00414.X

Posttherapy suppression of genital herpes simplex virus (HSV) recurrences and enhancement of HSV-specific T-cell memory by imiquimod in guinea pigs

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0906-6705.2006.00414.X

Efficacy of S26308 against guinea pig cytomegalovirus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0906-6705.2006.00414.X

The role of toll-like receptors in the pathogenesis and treatment of dermatological disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0906-6705.2006.00414.X

Gene expression in actinic keratoses: pharmacological modulation by imiquimod.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0906-6705.2006.00414.X

The 500 Dalton rule for the skin penetration of chemical compounds and drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0906-6705.2006.00414.X

Topical immunomodulation in dermatology: potential of toll-like receptor agonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0906-6705.2006.00414.X

Stimulation of interferon and cytokine gene expression by imiquimod and stimulation by Sendai virus utilize similar signal transduction pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0906-6705.2006.00414.X

Immunomodulating and antiviral activities of the imidazoquinoline S-28463.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0906-6705.2006.00414.X

Synthetic TLR agonists reveal functional differences between human TLR7 and TLR8.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0906-6705.2006.00414.X

Various members of the Toll-like receptor family contribute to the innate immune response of human epidermal keratinocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0906-6705.2006.00414.X

Mouse and human dendritic cell subtypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0906-6705.2006.00414.X

Plasmacytoid dendritic cells in immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0906-6705.2006.00414.X

Plasmacytoid dendritic cells--virus experts of innate immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0906-6705.2006.00414.X

Subsets of human dendritic cell precursors express different toll-like receptors and respond to different microbial antigens

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0906-6705.2006.00414.X

CD11c(+)B220(+)Gr-1(+) cells in mouse lymph nodes and spleen display characteristics of plasmacytoid dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0906-6705.2006.00414.X

Plasmacytoid dendritic cells produce cytokines and mature in response to the TLR7 agonists, imiquimod and resiquimod

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0906-6705.2006.00414.X

Innate antiviral responses by means of TLR7-mediated recognition of single-stranded RNA

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0906-6705.2006.00414.X

IPC: professional type 1 interferon-producing cells and plasmacytoid dendritic cell precursors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0906-6705.2006.00414.X

Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0906-6705.2006.00414.X

Identification and characterization of pDC-like cells in normal mouse skin and melanomas treated with imiquimod

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0906-6705.2006.00414.X

Systemic administration of a TLR7 ligand leads to transient immune incompetence due to peripheral-blood leukocyte depletion.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0906-6705.2006.00414.X

Efficacy of imiquimod for the expression of Bcl-2, Ki67, p53 and basal cell carcinoma apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0906-6705.2006.00414.X

Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: results from two phase III, randomized, vehicle-controlled studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0906-6705.2006.00414.X

Dosing with 5% imiquimod cream 3 times per week for the treatment of actinic keratosis: results of two phase 3, randomized, double-blind, parallel-group, vehicle-controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0906-6705.2006.00414.X

Selective impairment of TLR-mediated innate immunity in human newborns: neonatal blood plasma reduces monocyte TNF-alpha induction by bacterial lipopeptides, lipopolysaccharide, and imiquimod, but preserves the response to R-848.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0906-6705.2006.00414.X

Selected Toll-like receptor agonist combinations synergistically trigger a T helper type 1-polarizing program in dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0906-6705.2006.00414.X

Combined TLR and CD40 triggering induces potent CD8+ T cell expansion with variable dependence on type I IFN

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0906-6705.2006.00414.X

Direct stimulation of human T cells via TLR5 and TLR7/8: flagellin and R-848 up-regulate proliferation and IFN-gamma production by memory CD4+ T cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0906-6705.2006.00414.X

DNA sequences in cationic lipid:pDNA-mediated systemic toxicities

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0906-6705.2006.00414.X

Autoantigen, innate immunity, and T cells cooperate to break B cell tolerance during bacterial infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0906-6705.2006.00414.X

Maintenance of serological memory by polyclonal activation of human memory B cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0906-6705.2006.00414.X

Quantitative expression of toll-like receptor 1-10 mRNA in cellular subsets of human peripheral blood mononuclear cells and sensitivity to CpG oligodeoxynucleotides

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0906-6705.2006.00414.X

The immune response modifier resiquimod mimics CD40-induced B cell activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0906-6705.2006.00414.X

Molecular mechanisms of B lymphocyte activation by the immune response modifier R-848.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0906-6705.2006.00414.X

Plasmacytoid dendritic cells control TLR7 sensitivity of naive B cells via type I IFN.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0906-6705.2006.00414.X

Inhibition of IgE production by the imidazoquinoline resiquimod in nonallergic and allergic donors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0906-6705.2006.00414.X

Neurological complications of HIV infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0906-6705.2006.00414.X

Influenza virus and CNS manifestations

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0906-6705.2006.00414.X

Microglia activation in rat spinal cord by systemic injection of TLR3 and TLR7/8 agonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0906-6705.2006.00414.X

Death receptor-independent apoptosis in malignant melanoma induced by the small-molecule immune response modifier imiquimod

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0906-6705.2006.00414.X

Tumor-selective induction of apoptosis and the small-molecule immune response modifier imiquimod

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0906-6705.2006.00414.X

Imiquimod induced regression of clinically diagnosed superficial basal cell carcinoma is associated with early infiltration by CD4 T cells and dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0906-6705.2006.00414.X

Treatment of lentigo maligna (melanoma in situ) with the immune response modifier imiquimod

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0906-6705.2006.00414.X

Topical treatment of lentigo maligna melanoma with imiquimod 5% cream

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0906-6705.2006.00414.X

Mechanisms underlying imiquimod-induced regression of basal cell carcinoma in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0906-6705.2006.00414.X

Dendritic cells and tumor immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0906-6705.2006.00414.X

Spontaneous regression of human melanoma/nonmelanoma skin cancer: Association with infiltrating CD4+ T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0906-6705.2006.00414.X

Immune modulation and apoptosis induction: two sides of the antitumoral activity of imiquimod

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0906-6705.2006.00414.X

Plasmacytoid monocytes migrate to inflamed lymph nodes and produce large amounts of type I interferon

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0906-6705.2006.00414.X

10.1111/J.0906-6705.2006.00414.X

21 January 2018

Identifiers

DOI

1 reference

14 August 2017

1 reference